Biotech ETF Recovery Powered By Big Earnings Improvements

| February 10, 2017

article image
Though Trump spooked the industry by saying that drugmakers are “getting away with murder” and pledging to initiate a bidding process for drug pricing last month, losses reversed following his latest statements regarding drug prices and regulation. Trump promised to reduce regulations and streamline the approval process (read: Trump Attacks Biotech & Pharma: ETFs Bleed).

Spotlight

Polish Stem Cells Bank (PBKM)/ FamiCord Group

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than 1000 units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK .

OTHER ARTICLES

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | February 18, 2020

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Top 10 biotech IPOs in 2019

Article | February 24, 2020

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | February 12, 2020

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Spotlight

Polish Stem Cells Bank (PBKM)/ FamiCord Group

The Polish Stem Cells Bank (PBKM) is operating on the international market under the brand of FamiCord Group, which was founded in 2002. It is a stem cell bank, engaged in the acquisition, processing and long-term storage of stem cells taken from umbilical cord blood and other fetal tissues on behalf of parents – family banking. The aim of PBKM is to ensure access of the family for stem cells in case of need for therapy. As of 2017 FamiCord has released more than 30 units of cord blood for transplantatation and more than 1000 units of stem cells from other sources. Currently Famicord Group operates directly in Poland, Spain, Turkey, Latvia, Hungary, Romania, Italy and through business partners in Sweden, Ukraine, Serbia and UK .

Events